Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2740 - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Shigeru Tsuyuki

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

S. Tsuyuki1, K. Yamagami2, H. Yoshibayashi3, T. Sugie4, Y. Mizuno5, S. Tanaka6, H. Kato7, T. Okuno8, N. Ogura9, H. Yamashiro10, H. Takuwa11, Y. Kikawa12, T. Hashimoto13, T. Kato14, S. Takahara15, A. Yamauchi16, T. Inamoto17

Author affiliations

  • 1 Breast Surgery, Osaka Red Cross Hospital, 543-8555 - Osaka/JP
  • 2 Department Of Breast Surgery, Shinko Hospital, Kobe/JP
  • 3 Department Of Breast Surgery, Japanese Red Cross Wakayama Medical Cente, Wakayama/JP
  • 4 Department Of Breast Surgery,, Kansai Medical University Hospital, Osaka/JP
  • 5 Breast Surgery, Yokkaichi Municipal Hospital, 510-8567 - Yokkaichi/JP
  • 6 Breast Surgery, National Hospital Organization Osaka-Minami Medical Center, 586-8521 - Kawachinagano/JP
  • 7 Department Of Breast Surgery, Kobe City Medical Center General Hospital, Kobe/JP
  • 8 Department Of Breast Surgery, Kobe City Nishi-Kobe Medical Center, Kobe/JP
  • 9 Department Of Breast Surgery, Kansai Electric Power Hospital, Osaka/JP
  • 10 Breast Surgery, Tenri Hospital, 632-8552 - Tenri/JP
  • 11 Breast Surgery, Shiga General Hospital, 524-8524 - Moriyama/JP
  • 12 Breast Surgery, Kobe minimally invasive cancer center, 650-0046 - Kobe/JP
  • 13 Breast Surgery, Hashimoto Clinic, 658-0051 - Kobe/JP
  • 14 Breast Surgery, Yamato Takada Municipal Hospital, 635-8501 - Yamatotakada/JP
  • 15 Breast Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 530-8480 - Osaka/JP
  • 16 Breast Surgery, Nara Prefecture General Medical Center, 630-8581 - Nara/JP
  • 17 Health Care, Tenri Health Care University, 632-0018 - Tenri/JP
More

Resources

Abstract 2740

Background

No effective prophylactic managements are established for chemotherapy-induced peripheral neuropathy (CIPN). We developed a new, feasible method to prevent CIPN, using compression therapy with surgical gloves (SGs), called SG compression therapy, and recently reported that this method significantly reduced the overall occurrence of grade 2 or higher nanoparticle albumin-bound-paclitaxel (nab-PTX)-induced peripheral neuropathy (PN) from 76.1% to 21.4%, as SGs decreased the microvascular flow to each fingertip (Breast Cancer Res Treat. 2016; 160:61-67). To avoid the major disadvantages of PN for the non-SG-wearing patients by a randomized controlled trial, we investigated the efficacy and safety of SG compression therapy for nab-PTX induced PN in a multicenter single-armed confirmatory study, comparing to the incidence of 44.1% grade 2 or higher PN found in known literature, which we considered as a control group.

Methods

Primary breast cancer patients who received 260 mg/m2 of nab-PTX were eligible for this study. Patients wore two SGs of the same size, i.e., one size smaller than the size that fit their both hands, for 90 minutes. PN was evaluated at each treatment cycle using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and the Patient Neurotoxicity Questionnaire (PNQ). The temperature of each fingertip was measured by using thermography.

Results

Between October 2016 to June 2017, 61 patients were enrolled, and 58 were evaluated. The incidence of sensory PN of CTCAE grade 2 or higher was as low as 13.8% following SG compression therapy. The occurrence rate of grade 4 or higher PNQ responses, which indicate interference with activities of daily living, was also as low as 10.3%. A goodness-of-fit test using a chi-square test proved that the overall incidence of 13.8% grade 2 or higher PN obtained in this study is equal to 13% of the hypothesis-predicted value. All patients completed this study because they tolerated the compression from the SGs. SG compression therapy significantly reduced the temperature of each fingertip by 1.3–2.3 °C compared to that before chemotherapy.

Conclusions

This study demonstrated that SG compression therapy is effective and safe for reducing CIPN.

Clinical trial identification

University Hospital Medical Information Network (UMIN) Number: 000024836.

Legal entity responsible for the study

Kamigata Breast Cancer Study Group.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings